- Home
- GENK vs FGEN Comparison
GENK vs FGEN Comparison
Compare GENK & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- FGEN
- Stock Information
- Founded
- GENK 2011
- FGEN 1993
- Country
- GENK United States
- FGEN United States
- Employees
- GENK N/A
- FGEN 225
- Industry
- GENK Restaurants
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- FGEN Health Care
- Exchange
- GENK Nasdaq
- FGEN Nasdaq
- Market Cap
- GENK 16.3M
- FGEN 45.0M
- IPO Year
- GENK 2023
- FGEN 2014
- Fundamental
- Price
- GENK $3.12
- FGEN $11.14
- Analyst Decision
- GENK Strong Buy
- FGEN Strong Buy
- Analyst Count
- GENK 2
- FGEN 2
- Target Price
- GENK $7.00
- FGEN $146.50
- AVG Volume (30 Days)
- GENK 55.3K
- FGEN 37.7K
- Earning Date
- GENK 11-11-2025
- FGEN 11-11-2025
- Dividend Yield
- GENK 3.73%
- FGEN N/A
- EPS Growth
- GENK N/A
- FGEN N/A
- EPS
- GENK N/A
- FGEN N/A
- Revenue
- GENK $216,137,000.00
- FGEN $7,346,000.00
- Revenue This Year
- GENK $12.35
- FGEN N/A
- Revenue Next Year
- GENK $14.62
- FGEN N/A
- P/E Ratio
- GENK N/A
- FGEN N/A
- Revenue Growth
- GENK 10.67
- FGEN N/A
- 52 Week Low
- GENK $3.03
- FGEN $4.50
- 52 Week High
- GENK $10.33
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- GENK 40.06
- FGEN 53.16
- Support Level
- GENK $3.11
- FGEN $11.12
- Resistance Level
- GENK $3.39
- FGEN $12.53
- Average True Range (ATR)
- GENK 0.15
- FGEN 0.89
- MACD
- GENK 0.02
- FGEN -0.16
- Stochastic Oscillator
- GENK 25.00
- FGEN 30.48
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.